Transaction DateRecipientSharesTypePriceValue
23rd November 2020Srinivas Akkaraju500,000Grant/award etc.$10.00$5,000,000.00
18th November 2020David W Gryska50,000Open or private sale$2.39$119,500.00
18th November 2020David W Gryska60,000Exercise of derivative$1.64$98,400.00
17th November 2020David W Gryska100,000Open or private sale$2.40$240,000.00
9th November 2020Alpna Seth1,358Open or private sale$305.74$415,194.92
9th November 2020Alpna Seth3,125Exercise of derivative$125.05$390,781.25
9th November 2020Alpna Seth3,665Open or private sale$306.95$1,124,971.75
9th November 2020Alpna Seth1,898Exercise of derivative$179.84$341,336.32
5th November 2020David W Gryska4,500Open or private sale$180.60$812,699.10
4th November 2020Charles R Romp1,590Exercise of derivative$34.20$54,378.00
Seattle Genetics
Seattle Genetics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Seattle Genetics, Inc. is a biotechnology company. It engages in the development and commercialization of antibody-based therapies for the treatment of cancer. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.


Ticker: SGEN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1060736
Employees: 1605
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $117 M (-57%)
Inventory, Net: $90 M (0%)
Assets, Current: $1 B (13%)
Property, Plant and Equipment, Net: $185 M (19%)
Other Assets, Noncurrent: $17 M (-90%)
Assets: $2 B (-1%)
Accounts Payable, Current: $59 M (13%)
Liabilities, Current: $283 M (8%)
Other Liabilities, Noncurrent: $4 M (60%)
Common Stock, Value, Issued: $174 Th (1%)
Common Stock, Shares, Issued: $174 Th (1%)
Additional Paid in Capital, Common Stock: $3 B (3%)
Retained Earnings (Accumulated Deficit): $2 B (12%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (541%)
Stockholders' Equity (Parent): $2 B (0%)
Liabilities and Equity: $2 B (-1%)
Revenue: $278 M (-45%)
Research and Development: $198 M (-49%)
Operating Income/Loss: $94 M (-54%)